Patients Treated With ABL vs Patients Treated With TPTD: Number of Participants With Composite Endpoint of Nonfatal Myocardial Infarction (MI), Nonfatal Stroke, or In-hospital Cardiovascular Death
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
Measures 6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note | Source |
|---|---|---|---|---|---|---|
| Risk in group 1 | 0.02 | 0.0176 | 0.0228 | wilson | ClinicalTrials.gov | |
| Risk in group 2 | 0.0191 | 0.0167 | 0.0219 | wilson | ClinicalTrials.gov | |
| Risk difference, group 1 minus group 2 | 0.000907 | -0.00276 | 0.00458 | newcombe hybrid score | ClinicalTrials.gov | |
| Risk ratio, group 1 over group 2 | 1.05 | 0.869 | 1.26 | log | ClinicalTrials.gov | |
| Odds ratio, group 1 over group 2 | 1.05 | 0.867 | 1.27 | log | ClinicalTrials.gov | |
| Number needed to treat, for one more participant with the outcome on Patients Treated With ABL than on Patients Treated With TPTD | 1,100 | from the risk difference interval | the interval includes no difference | ClinicalTrials.gov |
Groups 2
Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code | Source |
|---|---|---|---|---|---|---|
| Group 1 | Patients Treated With ABL | Patients who filled ≥ 1 prescription for ABL (TYMLOS) as their index medication during the identification period. | 221 | 11,027 | OG000 | ClinicalTrials.gov |
| Group 2 | Patients Treated With TPTD | Patients who filled ≥ 1 prescription for TPTD (Forteo) as their index medication during the identification period. | 211 | 11,027 | OG001 | ClinicalTrials.gov |
Outcome 5
| Field | Value | Source |
|---|---|---|
| Type | SECONDARY | ClinicalTrials.gov |
| Title | Number of Participants With Composite Endpoint of Nonfatal Myocardial Infarction (MI), Nonfatal Stroke, or In-hospital Cardiovascular Death | ClinicalTrials.gov |
| Description | Cardiovascular safety was evaluated based only on events occurring from the beginning of the index period through 19 months. The date of the first prescription claim for either abaloparatide or teriparatide during the identification period was considered the index date. Cardiovascular events (MI and stroke) were defined as the first post-index incidence recorded on a hospital claim or physician claim. A validated claims-based algorithm was used to identify deaths, based on hospital discharge status, that are likely to be caused by cardiovascular events. Patients were followed for up to 18 months while on treatment plus 30 days follow-up, or until their first cardiovascular event (MI or stroke) or hospital death, whichever came first. | ClinicalTrials.gov |
| Time frame | From index date up to 19 months | ClinicalTrials.gov |
| Population | All patients meeting the study inclusion/exclusion criteria and selected after PS-matching. | ClinicalTrials.gov |
Trial 8
| Field | Value | Source |
|---|---|---|
| Title | Real-world Effectiveness and Cardiovascular Safety Study of Abaloparatide in Postmenopausal Women | ClinicalTrials.gov |
| NCT number | NCT04974723 | ClinicalTrials.gov |
| Phases | ClinicalTrials.gov | |
| Conditions | Osteoporosis, Postmenopausal | ClinicalTrials.gov |
| Interventions | Abaloparatide, Teriparatide | ClinicalTrials.gov |
| Lead sponsor | Radius Health, Inc. | ClinicalTrials.gov |
| Results first posted | 2024-04-19 | ClinicalTrials.gov |
| Results on ClinicalTrials.gov | https://clinicaltrials.gov/study/NCT04974723?tab=results | ClinicalTrials.gov |
Source 4
| Field | Value | Source |
|---|---|---|
| Release | trial-comparisons-2026-03-23-0.1.0 | ClinicalTrials.gov |
| Release manifest SHA-256 | f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57 | ClinicalTrials.gov |
| AACT copy | 2026-03-23 | ClinicalTrials.gov |
| Tables read | outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet | ClinicalTrials.gov |
Release trial-comparisons-2026-03-23-0.1.0
ClinicalTrials.gov's posted results, through CTTI's AACT: ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299 ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
ClinicalTrials.gov: none stated ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.